SynthesisMedicine2026
Three traditional Chinese patent medicines combined with transarterial chemoembolization for primary liver cancer: A systematic review and Bayesian network meta-analysis.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the objective response rate (ORR) and disease control rate of 3 Chinese herbal medicines (Compound Banmao Capsule, Huaier Granule, and Jinlong Capsule) combined with transarterial chemoembolization (TACE) for primary liver cancer using Bayesian network meta-analysis.
methodsWe systematically searched randomized controlled trials (RCTs) across the Cochrane Library, Embase, PubMed, Web of Science, VIP Database for Chinese Technical Periodicals, China National Knowledge Infrastructure, and Wanfang databases from their inception to January 10, 2025. Two researchers independently screened the literature, extracted data, and assessed study quality using predefined inclusion and exclusion criteria. A Bayesian network meta-analysis was performed using RStudio to synthesize and hierarchically rank interventions by effect size in the included RCTs. This review was registered with PROSPERO (CRD420251019361).
resultsThirty-one RCTs involving 2604 patients with primary liver cancer were included. The network meta-analysis showed that, compared with TACE alone: Compound Banmao Capsule ranked highest for ORR (OR = 1.50, 95% CI: 1.08, 2.08), followed by Huaier Granule (OR = 1.47, 95% CI: 1.05, 2.05) and Jinlong Capsule (OR = 1.30, 95% CI: 1.02, 1.65). For disease control rate, the ranking was Compound Banmao Capsule (OR = 1.21, 95% CI: 0.76, 1.93), Jinlong Capsule (OR = 1.17, 95% CI: 0.85, 1.59), and Huaier Granule (OR = 1.12, 95% CI: 0.66, 1.91).
conclusionFor ORR, the combination of the 3 Chinese herbal medicines with TACE showed superior efficacy to TACE monotherapy, with Compound Banmao Capsule demonstrating the greatest therapeutic potential among the interventions evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.